Table 1.
Patients’ characteristics at inclusion.
| Characteristics | Value | % | n |
|---|---|---|---|
| Age (y; median and range) | 62.8 (29–83) | 105 | |
| Sex ratio (F/M) | 45/60 | - | |
| Indication for PET/CT | - | ||
| Initial staging | 41 | 39.0 | - |
| Suspicion of recurrence or progression | 47 | 44.8 | - |
| Suspicion of GEP-NET on morphological exams | 17 | 16.2 | - |
| Secretion | - | ||
| None | 84 | 80.0 | - |
| Carcinoid syndrome | 9 | 8.6 | - |
| Insulin | 5 | 4.8 | - |
| Gastrin | 6 | 5.7 | - |
| Glucagon | 1 | 1.0 | - |
| NET Tumoral grade (WHO 2019) | 102 | ||
| 1 | 42 | 41.2 | - |
| 2 | 55 | 53.9 | - |
| Unknown | 5 | 4.9 | - |
| Primary tumor site confirmed or suspected at inclusion | 105 | ||
| Pancreas | 46 | 43.8 | - |
| Jejunum and ileum | 30 | 28.6 | - |
| Rectum | 4 | 3.8 | - |
| Stomach | 4 | 3.8 | - |
| Duodenum | 4 | 3.8 | - |
| Appendix | 1 | 1.0 | - |
| Colon | 1 | 1.0 | |
| Occult | 15 | 14.3 | - |
| Localized GEP-NET at inclusion | 33 | 31.4 | |
| Locoregional lymph node involvement without visceral metastases GEP-NET (N+M0) at inclusion | 15 | 14.3 | - |
| Distant metastatic GEP-NET (N0 or N+M+) at inclusion | 57 | 54.3 | - |
GEP: gastroenteropancreatic; NET: neuroendocrine tumor; PET/CT: positron emission tomography combined with computed tomography; WHO: World Health Organization.